Hollings Renton Biography and Net Worth

Director of AnaptysBio

Hollings Renton has previously served as the Chief Executive Officer and President of Onyx Pharmaceuticals from 1993 to 2008 and as the Chairman of the Board from 2000 to 2008. From 1991 to 1993, Mr. Renton served as President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, following its acquisition of Cetus Corporation. He served as President of Cetus Corporation from 1990 to 1991, as Chief Operating Officer from 1987 to 1990, and as Chief Financial Officer from 1983 to 1987. Mr. Renton serves as chairman of the board of Portola Pharmaceuticals, Inc. and serves on the board of Zymeworks, Inc. He previously served on the boards of directors of Cepheid, Inc., Kythera Biopharmaceuticals, Inc., Rigel Pharmaceuticals, Inc., Affymax, Inc., Sangstat Medical Corporation, Special Olympics Northern California and the Biotechnology Industry Organization. Mr. Renton received a B.S. in Mathematics from Colorado State University and a M.B.A. from the University of Michigan.

What is Hollings Renton's net worth?: The estimated net worth of Hollings Renton is at least $214.98 thousand as of July 2nd, 2025. Mr. Renton owns 4,965 shares of AnaptysBio stock worth more than $214,985 as of December 5th. This net worth estimate does not reflect any other investments that Mr. Renton may own. Learn More about Hollings Renton's net worth.
How do I contact Hollings Renton?: The corporate mailing address for Mr. Renton and other AnaptysBio executives is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. AnaptysBio can also be reached via phone at (858) 362-6295 and via email at [email protected]. Learn More on Hollings Renton's contact information.
Has Hollings Renton been buying or selling shares of AnaptysBio?: Hollings Renton has not been actively trading shares of AnaptysBio over the course of the past ninety days. Most recently, Hollings Renton sold 20,925 shares of the business's stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $23.57, for a transaction totalling $493,202.25. Following the completion of the sale, the director now directly owns 4,965 shares of the company's stock, valued at $117,025.05. Learn More on Hollings Renton's trading history.
Who are AnaptysBio's active insiders?: AnaptysBio's insider roster includes Daniel Faga (President & CEO), Dennis Fenton (Director), Paul Lizzul (Chief Medical Officer), Eric Loumeau (COO), Dennis Mulroy (CFO), Hollings Renton (Director), and Hamza Suria (CEO). Learn More on AnaptysBio's active insiders.
Are insiders buying or selling shares of AnaptysBio?: In the last twelve months, AnaptysBio insiders bought shares 2 times. They purchased a total of 71,830 shares worth more than $928,242.98. In the last twelve months, insiders at the biotechnology company sold shares 1 times. They sold a total of 20,925 shares worth more than $493,202.25. The most recent insider tranaction occured on July, 2nd when Director Hollings Renton sold 20,925 shares worth more than $493,202.25. Insiders at AnaptysBio own 33.5% of the company. Learn More about insider trades at AnaptysBio.
Information on this page was last updated on 7/2/2025.

Hollings Renton Insider Trading History at AnaptysBio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/2/2025	Sell	20,925	$23.57	$493,202.25	4,965
7/15/2024	Sell	10,000	$30.64	$306,400.00	1,950
6/18/2024	Sell	1,950	$23.16	$45,162.00	1,950

Hollings Renton Buying and Selling Activity at AnaptysBio

AnaptysBio Company Overview

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Today's Range

Now: $43.30

$42.63

$45.32

50 Day Range

MA: $35.31

$23.27

$43.76

2 Week Range

Now: $43.30

$12.21

$45.32

Volume

591,640 shs

Average Volume

743,185 shs

Market Capitalization

$1.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.29